price month
 close
result exceed estim consensu abax
pre-announce result ahead jan earn releas
target revenu million repres
acceler albeit easi comp estim
consensu littl disclosur drive upsid
gross margin target howev came lighter
expect await greater compani disclosur front
well still pre-tax profit prelim guidanc rang million
better plan vs estimate consensu million
pursuant tax cut job act tax rate move
bp yoy exclud one-tim charg drop
bp repres slightli less favor
tax run rate initi analysi consequ boost
ep estim
respect tp move
focu new direct initi upcom investor present
focu recent initi bolster direct sale effort pleas see
previou note abax waver distribut strategi greater detail
strategi shift abax argu lack distribut support
largest disadvantag past decad establish relationship
top distributor recent year clearli lost faith
distribut add current platform abax shift hybrid
approach distributor could de-emphas abax product
abax consum go distribut howev latest outlook
indic occur yet given latest revenu upsid
suspect proce tax reform help facilit new initi
acknowledg rational behind shift address weak
distribut support undertak come without challeng
given level invest seen competitor idxx effort
dynam clearli call question competit platform
henc under-perform rate risk includ shift fundament demand
valuat metric
number share
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
abax lead manufactur point-of-car diagnost
equip particip anim human health care
set develop portabl blood instrument rapidli measur
blood constitu clinician offic set
price jan rate under-perform target price analyst erin wright
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
cash-flow financ activ
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
 close
gain veterinari substanti acceler human medic
placement significantli improv relationship vendor
partner rapid traction/launch new pipelin
grey sky valuat assum increasingli
continu difficulti distribut relationship meaning
contribut new product launch unexpect weak
broader industri demand
compani mention price
